Læknablaðið - 15.06.2007, Qupperneq 16

FRÆÐIGREINAR / LANGVINN LUNGNATEPPA
eru margir sem ekki hafa reykt. Hvort um er að
ræða einstaklinga sem fyrir áratugum höfðu teppu-
sjúkdóm í lungum (til dæmis astma) sem hvorki
var greindur eða meðhöndlaður verður ekki skýrt
á grunni þessarar þverskurðarrannsóknar. Einnig
hefur verið bent á að ef hlutfallið FEVl/FVC <70
er notað fyrir eldri einstaklinga þá leiði það líkleg-
ast til ofmats á LLT meðal þeirra (34). Bent hefur
verið á aðrar tölfræðilegar aðferðir sem nota mætti
við túlkun blástursprófa (36), en ekki hefur náðst
samstaða um þær enn.
Pessi rannsókn sýnir háa tíðni langvinnrar
lungnateppu á íslandi þegar fylgt er alþjóðlega
viðurkenndum og samræmdum vísindavinnu-
brögðum. Upplýsingarnar munu nýtast yfirvöldum
vel til þess að forgangsraða verkefnum í heilbrigð-
isþjónustu.
Þakkir
Höfundar vilja þakka þeim sem þátt tóku í rann-
sókninni. Einnig Lovísu Guðmundsdóttur og
Sigrúnu Guðmundsdóttur fyrir frábæra aðstoð
við framkvæmd og söfnun gagna. Eftirfarandi
læknanemum fyrir vinnu við gagnasöfnun: Önnu
Björnsdóttur, Guðrúnu Fönn Tómasdóttur,
Jóhanni Matthíasi Haukssyni, Martin Inga
Sigurðssyni, Óla Hilmari Ólafssyni, Ólöfu Birnu
Margrétardóttur, Sigurði James Þorleifssyni og
Vöku Ýr Sævarsdóttur. Vísindasjóður Landspítala
og lyfjafyrirtækin GlaxoSmithKline og Astra-
Zeneca studdu rannsóknina fjárhagslega, en höfðu
engin áhrif á framkvæmd, túlkun á niðurstöðum
eða skrif.
Heimildir
1. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd
SS. On behalf of the GOLD Scientific Committee, Global
Strategy for the Diagnosis, Management, and Prevention of
Chronic Obstructive Pulmonary Disease. NHLBL/WHO
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) Workshop Summary. Am J Respir Crit Care Med
2001; 163:1256-1276. www.goldcopd.org
2. Murray CJL, Lopez AD. Alternative Projections of Mortality
and Disability by cause 1990-2020: Global Burden of Disease
Study. Lancet 1997; 349:1498-504.
3. Gulsvik A, Boman G, Dahl R, Gislason T, Nieminen M. The
burden of obstructive lung disease in the Nordic countries.
Respir Med 2006; 100 Suppl A:S2-9.
4. Jemal A, Ward E, Hao Y, Thun M. Trends in the Leading
Causes of Death in the United States, 1970-2002. JAMA 2005;
294:1255-9.
5. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of
different definitions of airway obstruction. Eur Respir J 2003;
22:268-73.
6. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD
Prevalence Estimates: What is the True Burden of Disease?
Chest 2003; 123:1684-92.
7. Celli BR, MacNee W, and committee members. ATS/ERS Task
force: Standards for the diagnosis and treatment of patients
with COPD: A summary of the ATS/ERS position paper. Eur
RespirJ 2004; 23:932-46.
8. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive
lung disease and low lung function in adults in the United
States. Arch Intem Med 2000; 160:1683-89.
9. Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai
A, Kuriyama T, et al. COPD in Japan: the Nippon COPD
Epidemiology study. Respirology 2004; 9:458-65.
10. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et
al. Prevalence of Chronic Obstmctive Pulmonary Disease in
Korea: A population- based spirometry survey. Am J Respir
Crit Care Med 2005; 172:842-7.
11. Pena VS, Miravitlles M, Gabriel R, Jimenez-Ruiz CA,
Villasante C, Masa JF, et al. Geographic Variations in
Prevalence and Underdiagnosis of COPD: Results of the
IBERPOC Multicentre Epidemiological Study. Chest 2000;
118:981-9.
12. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez
MV, Valdivia G, et al. Chronic obstructive pulmonary disease
in five Latin American cities (the Platino study): a prevalence
study. Lancet 2005; 366:1875-81.
13. Wise RA, Kanner RE, Lindgren P, Connett JE, Altose MD,
Enright PL, et al. The effect of smoking intervention and an
inhaled bronchodilator on airways reactivity in COPD: the
Lung Health Study. Chest 2003; 124:449-58.
14. Gíslason Þ,Tómasson K. Dánartíðni vegna astma, langvinnrar
berkjubólgu og lungnaþembu. Læknablaðið 1994; 80:239-43.
15. de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer
J, Neukirch F, et al. An international survey of chronic
obstructive pulmonary disease in young adults according to
GOLD stages. Thorax 2004:59; 120-5.
16. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA,
Menezes AM, et al. The Burden of obstructive Lung Disease
Initiative (BOLD): Rationale and Design. COPD 2005; 2:277-
83.
17. Mannino DM, Doherty DE, Buist AS. Global Initiative on
Obstructive Lung Disease (GOLD) classification of lung
disease and mortality: findings from the Atherosclerosis Risk
in Communities (ARIC) study. Respir Med 2006; 100:115-22.
18. American Thoracic Society Statement: Standardization of
spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152:
1107-36.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric
Reference Values from a Sample of the General US
Population. Am J Respir Crit Care Med 1999; 159:179-87.
20. Lohr SL. Sampling: Design and Analysis, Duxbury 1999:268-
9.
21. Soriano JB,MaierWC,Egger P,Visick G,Thakrar B,Sykes J,et
al. Recent trends in physician diagnosed COPD in women and
men in the UK.Thorax 2005;55:789-94.
22. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson
AC, Jonsson E, et al. Not 15 But 50% of smokers develop
COPD? - Report from the Obstructive Lung Disease in
Northern Sweden Studies. Repir Med 2003; 97:115-22.
23. Chapman KR, Mannino DM, Soriano JB, Vermeire PA,
Buist AS, Thun MJ, et al. Epidemiology and costs of chronic
obstructive pulmonary disease. Eur Respir J 2006; 27:188-207.
24. Connett JE, Murray RP, Buist AS, Wise RA, Bailey WC,
Lindgren PG, et al. Lung Health Study Research Group.
Changes in smoking status affect women more than men:
Results of the Lung Health Study. Am J Epidemiol 2003; 157:
973-9.
25. Magnússon S, Gíslason T. Chronic bronchitis in Icelandic
males and quality of life. Scand J Prim Health Care 1999; 17:
100-4.
26. Benediktsdóttir B, Tómasson K, Gíslason T. Undiagnosed
chronic bronchitis among women. Abstract. Nordic Lung
Congress. Copenhagen june 10-12,1999.
27. Janson C, Chinn S, Jarvis D, Zock JP, Toren K, Burney P.
Effect of passive smoking on respiratory symptoms, bronchial
responsiveness, lung function, and total serum IgE in the
European Community Respiratory Health Survey: a cross-
sectional study. Lancet 2001; 35:2103-9.
28. Kiinzli N, Marco de R, Chinn'S, Jarvis D, Svanes C, Heinrich J,
et al. Changes in active and passive smoking in the European
Community Respiratory Health Survey. Eur Respir J 2006; 27:
517-24.
29. de Marco R, Accordini S, Cerveri I, Corsico A, Anto JM,
Kunzli N, et al. Incidence of COPD in a Cohort of Young
Adults According to the Presence of Chronic Cough and
Phlegm. Am J Respir Crit Care Med 2007; 175:32-9.
476 Læknablaðið 2007/93